Investment
Features
FeesSafety
Academy
More
Pluang+

Hammerhead AI partners with TD SYNNEX to distribute ORCA platform, unlocking stranded power for AI data centers.

Market News
15 Sep 2026
PRNewsWire
View Source
Bullish
Hammerhead AI partners with TD SYNNEX to distribute ORCA platform, unlocking stranded power for AI data centers.

Hammerhead AI and TD SYNNEX have formed a strategic partnership to distribute Hammerhead's ORCA software, which converts unused power in data centers into AI-ready capacity. TD SYNNEX will leverage its global reseller network to help customers quickly unlock power for AI workloads without waiting for new grid upgrades, addressing a key bottleneck in AI deployment. This collaboration supports TD SYNNEX's Destination AI program and aims to accelerate AI infrastructure deployment by providing a standardized, scalable solution. The partnership targets neoclouds, AI labs, colocation providers, and enterprises to increase AI capacity efficiently amid growing inference workload demands.

Hammerhead AI and TD SYNNEX's strategic collaboration to expand AI-ready power capacity provides context for technology sector activity on Pluang. For readers following technology stocks, here is Pluang's market snapshot as of Sep 15, 2026 19:15 WIB: out of 150 priced US technology stocks, 58 rose and 86 fell. Notable price changes include ServiceNow Inc (NOW) at USD 138.77 down 2.51%, HubSpot Inc (HUBS) at USD 244.51 down 2.40%, and Atlassian Corporation PLC (TEAM) at USD 188.20 down 2.37%.

More News

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...

Company Fundamentals
Neutral
20 minutes ago
Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...

Analyst Insights
Bullish
1 hour ago
Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...

Analyst Insights
Bullish
1 hour ago
Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...

Analyst Insights
Bullish
2 hours ago
$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

An investment of $10,000 in Marvell stock a decade ago has grown to approximately $206,000 today. Achieving the same growth again would require an annual earnings increase of 35%. This highlights Marvell's strong past performance and the challenge of...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App